Kyntra Bio (KYNB) & Its Competitors Head to Head Review

Kyntra Bio (NASDAQ:KYNB) is one of 457 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its competitors? We will compare Kyntra Bio to similar companies based on the strength of its risk, valuation, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Institutional and Insider Ownership

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 39.3% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 2.0% of Kyntra Bio shares are held by company insiders. Comparatively, 14.0% of shares of all “Pharmaceutical Preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility and Risk

Kyntra Bio has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Kyntra Bio’s competitors have a beta of 5.46, suggesting that their average share price is 446% more volatile than the S&P 500.

Profitability

This table compares Kyntra Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,598.55%	N/A	-26.27%
Kyntra Bio Competitors	-2,628.08%	-359.45%	-43.11%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Kyntra Bio and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1	0	0	1	2.50
Kyntra Bio Competitors	4891	9971	15995	376	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 135.25%. Given Kyntra Bio’s competitors higher probable upside, analysts clearly believe Kyntra Bio has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Kyntra Bio and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kyntra Bio	$29.62 million	-$47.58 million	0.15
Kyntra Bio Competitors	$427.66 million	-$67.56 million	-10.73

Kyntra Bio’s competitors have higher revenue, but lower earnings than Kyntra Bio. Kyntra Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Kyntra Bio beats its competitors on 8 of the 13 factors compared.

Kyntra Bio Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.